Rehabilitation-dependent motor recovery after cerebral ischemia is associated with functional reorganization of residual cortical tissue. Recovery is thought to occur when remaining circuitry surrounding the lesion is "retrained" to assume some of the lost function. This reorganization is in turn supported by synaptic plasticity within cortical circuitry and manipulations that promote plasticity may enhance recovery. Activation of the cAMP/CREB pathway is a key step for experience-dependent neural plasticity. Here we examined the effects of the prototypical phosphodiesterase inhibitor 4 (PDE4) rolipram and a novel PDE inhibitor (HT-0712), known to enhance cAMP/CREB signaling and cognitive function, on restoration of motor skill and cortical function after focal cerebral ischemia. Adult male rats were trained on a skilled reaching task to establish a baseline level of motor performance. Intracortical microstimulation was then used to derive high-resolution maps of forelimb movement representations within the caudal forelimb area of motor cortex contralateral to the trained paw. A focal ischemic infarct was created within approximately 30% of the caudal forelimb area. The effects of administering either rolipram or the novel PDE4 inhibitor HT-0712 during rehabilitation on motor recovery and restoration of movement representations within residual motor cortex were examined. Both compounds significantly enhanced motor recovery and induced an expansion of distal movement representations that extended beyond residual motor cortex. The expansion beyond the initial residual cortex was not observed in vehicle injected controls. Furthermore, the motor recovery seen in the HT-0712 animals was dose dependent. Our results suggest that PDE4 inhibitors during motor rehabilitation facilitate behavioral recovery and cortical reorganization after ischemic insult to levels significantly greater than that observed with rehabilitation alone. R ecovery from brain injury can be thought of as a relearning process whereby spared neural tissue is retrained to compensate for lost or impaired functions. The neural mechanisms underlying recovery appear to involve reorganization of remaining neural circuitry through changes in synaptic connectivity within residual neural tissue.
R
ecovery from brain injury can be thought of as a relearning process whereby spared neural tissue is retrained to compensate for lost or impaired functions. The neural mechanisms underlying recovery appear to involve reorganization of remaining neural circuitry through changes in synaptic connectivity within residual neural tissue. 1 Therefore manipulations that promote synaptic plasticity may enhance experience-dependent recovery of function after brain injury.
Motor impairments are the most common deficit observed after stroke. Furthermore, recovery of motor function occurs to varying degrees with motor rehabilitation depending on the severity of the injury. 2, 3 The neural correlates of motor relearning in the damaged brain appear to involve compensation within residual motor areas. [4] [5] [6] Motor impairments and loss of microstimulation-evoked movement representations after stroke can be overcome with extensive motor rehabilitation. 4, 7, 8 Furthermore, in some cases the restoration of motor maps is accompanied by a reorganization of movement representations such that representations lost within the infarction can reemerge within new areas of cortex. 4, 8, 9 Hence, changes in motor map size and topography may represent a surrogate marker of motor recovery.
The reorganization of cortical movement representations is likely mediated by synaptic plasticity within intracortical microcircuitry. 1, 10 Regions of motor cortex that undergo redistribution of movement representations during skill learning also show increases in synapse number. 11, 12 Importantly, these same regions also demonstrate enhanced synaptic responses after skill learning. 13, 14 Furthermore, manipulations that alter synaptic strength or number also change motor map topography. The induction of cortical long-term potentiation (LTP) causes an increase in motor map area and synapse number, 13 whereas long-term depression causes a reduction in map area and synapse number. 15 Thus the topography and size of motor maps is dependent on synaptic efficacy within the motor cortex.
Genetic, pharmacological, and electrophysiological studies in a variety of organisms have underscored the importance of the cAMP/CREB pathway in synaptic plasticity, learning, and memory. [16] [17] [18] [19] [20] [21] [22] [23] [24] Pharmacological agents that inhibit this signaling pathway impair memory formation. [25] [26] [27] Conversely, administration of the type IVspecific phosphodiesterase inhibitors (PDE4) that enhance cAMP/CREB signaling, facilitate memory in normal and aged rodents. 20, [28] [29] [30] Importantly, the PDE4 inhibitors rolipram and HT-0712 also ameliorate memory deficits in a mouse model of Rubinstein-Taybi syndrome. These mice carry a mutation in CREB binding protein and show several developmental and mental abnormalities similar to patients with Rubinstein-Taybi syndrome. 31 In addition, cognitive improvements are also observed in a mouse model of Alzheimer's disease after enhancement of cAMP/CREB signaling with rolipram. 32 Within the cerebral cortex, cAMP signaling is important for functional reorganization and plasticity of both visual [33] [34] [35] and somatosensory cortical areas. 36, 37 Activation of the cAMP pathway is required for induction of LTP within the motor cortex 38 and may therefore be required for motor map reorganization. 13 Long-term potentiation can also be induced in a cAMP/CREB dependent manner via administration of brain derived neurotophic factor (BDNF) 39 and human subjects with a BDNFval 66 met polymorphism fail to show reorganization of cortical movement representations in response to motor training. 40 Thus, the cAMP/CREB pathway may be involved in reorganization of motor maps that occurs in response to learning in the intact brain and relearning in the damaged brain.
Given that (a) motor map reorganization is observed with motor recovery after stroke; (b) map reorganization is dependent on synaptic plasticity; and (c) synaptic plasticity is in turn regulated by the cAMP/CREB pathway, we reasoned that drugs which modulate CREB function by enhancing cAMP signaling might yield an effective treatment for rehabilitation-dependent motor recovery after brain injury. Here, we demonstrate that PDE4 inhibitors, rolipram and HT-0712 enhance rehabilitation-dependent motor recovery and cortical plasticity.
METHODS

Subjects
For all experiments, adult (90 days old) male LongEvans hooded rats (350-420 g) were group housed (2 animals/cage) in standard laboratory cages. Animals were on a 12:12-hour light/dark cycle throughout the experiment within the Canadian Centre for Behavioural Neuroscience vivarium. Animals in all 3 experiments were subjected to the same pretraining, motor mapping, and infarction procedures described below. All procedures were conducted in accordance with and approved by the Canadian Council on Animal Care and the University of Lethbridge Animal Welfare Committee.
Skilled Reach Training
Over the course of several days, all animals were placed on a restricted diet until they reached 90% of their original body weight. A brief period of pretraining was then given to familiarize the rats with the reaching task. This involved placing them into test cages (10 cm × 18 cm × 10 cm) with floors constructed of 2-mm bars, 9 mm apart edge to edge. A 4-cm wide and 5-cm deep tray filled with food pellets (45 mg; Bioserv) was mounted on the front of the cage. The rats were required to reach outside the cage and retrieve pellets from the tray. All rats remained in pretraining until they had successfully retrieved 10 pellets (approximately 1 h/day for 2 days). After pretraining, the rats were placed into a Plexiglas cage (11 cm × 40 cm × 40 cm) with a 1-cm slot located at the front of the cage. Animals were trained for 20 minutes each day to reach through the slot and retrieve food pellets from a table outside the cage. 12, 41 Rats were permitted to use either limb and the preferred limb was noted for each animal. Each session was videotaped and later used to assess reaching performance. A successful reach was scored when the animal grasped the food pellet, brought it into the cage, and to its mouth without dropping the pellet. The percentage of successful reaches [(number of successful retrievals/ the total number of reaches) × 100] was then calculated. Animals were trained for approximately 2 weeks on this task to establish a baseline measure of motor performance. Baseline was defined as the average accuracy across the 3 final days of training. Animals failing to achieve a mean of reaching accuracy of 40% across 3 consecutive days were not used in the study. Animals were also assigned to experimental conditions in a manner that counterbalanced prestroke reaching accuracy. This was to ensure that reaching performance prior to infarction was similar across conditions.
Motor Mapping
Within 2 days of the final training session, standard intracortical microstimulation (ICMS) techniques were used to generate detailed maps of the caudal forelimb area (CFA) of the motor cortex contralateral to the trained forelimb. 42, 43 Prior to surgery animals were anesthetized with ketamine hydrochloride (70 mg/kg i.p.) and xylazine (5 mg/kg i.p.). Animals received low levels of isofluorane (0.15%) and supplemental doses of ketamine (20 mg/kg i.p.) as needed. Under sterile conditions, a craniotomy was performed over the motor cortex contralateral to the trained paw of each animal. To prevent edema, a small puncture was made in the cisterna magna prior to removing the skull and dura. The exposed cortex was then covered in warm saline (37°C). A digital image of the cortical surface was taken and a 375-µm grid was superimposed onto the image. A glass microelectrode (controlled by a hydraulic microdrive) was used to make systematic penetrations across the cortex using the cortical surface image and grid as a guide. At each penetration site, the electrode was lowered to approximately 1550 µm (corresponding to cortical layer V). Stimulation consisted of thirteen, 200-µs cathodic pulses delivered at 350 Hz from an electrically isolated stimulation circuit. Animals were maintained in a prone position with the forelimb consistently supported. Sites where no movement was detected at ≤60 µA were recorded as unresponsive. Forelimb movements were classified as either distal (wrist/digit) or proximal (elbow/shoulder), and representational maps were generated from the pattern of electrode penetrations. The CFA was defined by a medial boundary of vibrissa representations, a lateral and caudal boundary of nonresponse sites and a rostral boundary of head and neck representations. [42] [43] [44] An image analysis program (CANVAS v. 3.5) was used to calculate the areal extent of the CFA for each animal.
Focal Infarction
Focal ischemic infarcts were created within CFA via bipolar electrocoagulation of surface vasculature. 4, 8 The infarct targeted primarily the distal forelimb representations but in some cases included small regions of proximal representations. The coagulated vessels included fine arterial and venous capillaries as well as larger vessels but specifically avoided any bypassing arteries supplying other cortical areas. Coagulation was continued until all vessels within the targeted area were no longer visible and the tissue appeared white (Fig. 1) . The infarcted area occupied approximately 30% of the total CFA. After infarction, a sheet of gel film was placed onto the exposed cortex and tucked beneath the skull. The cavity was then filled with gel foam and covered with a nonexothermic dental acrylic (Wave Polyflow) and cured under ultraviolet light. The wound was sutured and the animals were allowed to recover for approximately 5 days before being placed into rehabilitation training.
Assessing Residual Motor Map Area and Topography
Within 1 day of the final rehabilitation training session, ICMS was again used to generate a second map of the CFA contralateral to the trained forelimb. Prior to surgery animals were anesthetized with ketamine hydrochloride (70 mg/kg i.p.) and xylazine (5 mg/kg i.p.), receiving xylazine (0.02 mg/kg i.m.) and ketamine (20 mg/kg i.p.) as needed. Furthermore, animals were placed on isofluorane (0.15%, 1.5% O 2 ) when needed. The dental polymer, gel film, and gel foam were removed and the exposed cortex covered in warm silicon oil. Mapping procedures were identical to those used in the initial mapping (see above). Infarct area was calculated by outlining the cauterized area on the digital image if the cortical surface obtained from the first map. The area is clearly visible as a bleached or whitened area because of the loss of blood flow. Residual CFA prior to rehabilitation (Resid-PreRehab) was defined as the total area of CFA minus the area of infarct. Residual CFA postrehabilitation (Resid-PostRehab) was the total area of CFA after rehabilitation. The percentage change in residual CFA was then calculated as [(Res-PostRehab) − (Res-PreRehab)/100]. In addition, the percentage of residual CFA that was occupied by distal movement representations was calculated both prerehabilitation and postrehabilitation. Distal movement representations were analyzed because wrist/digit movement representations expand during both normal skill learning 12, 42, 43 and recovery of skill after cortical injury. 8 
EXPERIMENT 1 Motor Rehabilitation and Drug Treatment
A total of 30 animals received focal infarction within the CFA contralateral to their preferred (reaching) paw. After a 5-day recovery period, 20 of the animals were placed into a motor rehabilitation program that consisted of being trained daily for 20 minutes on the skilled reaching task described above for 10 consecutive days. Of these animals, half were administered 0.10 mg/kg (i.p.; n = 10) rolipram (Sigma) and half received a similar volume of vehicle solution (1% DMSO/PBS i.p.; n = 10) 20 minutes prior to the daily training session. This dosage and timing was chosen based on previous work showing the protocol to be effective in enhancing memory and inducing synaptic plasticity. 20 Training sessions were again videotaped and reaching accuracy was assessed daily as described above. Final motor recovery was assessed by averaging each animal's performance over the last 2 days of training and dividing this by the prestroke accuracy. A third group of animals received neither drug nor rehabilitative training (nontrained; n = 10). These animals received a single probe reaching session 10 days later to assess reaching performance. A repeated measures analysis of variance (ANOVA) with TIME as a within-subject factor and CONDITION as a between-subject factor was used to analyze treatment effects for reaching accuracy. A Fisher's protected least significant difference (PLSD) (P < .05) test was then used to determine significant mean differences.
EXPERIMENT 2 Motor Rehabilitation and Drug Treatment
A total of 61 animals received focal infarction within the CFA contralateral to their preferred paw after pretraining. Animals were allowed to recover for 5 days before being placed into a motor rehabilitation program that consisted of being trained daily for 20 minutes on the skilled reaching task described above for 10 consecutive days. Animals were randomly assigned to either a vehicle (n = 15), 0.10 mg/kg (n = 7), 0.15 mg/kg (n = 15), 0.30 mg/kg HT-0712 (n = 16) or 0.10 mg/kg × 2 HT-0712 (n = 8) condition. All animals received injections (i.p.) 20 minutes prior to the daily training session with the exception of the 0.10 mg/kg × 2 HT-0712 animals that received a second injection 3 hours after training. The sessions were videotaped and reaching accuracy was assessed as described above. Final motor recovery was assessed by averaging performance over the last 2 days of training.
HT-0712 was developed and supplied by Helicon Therapeutics Inc. A repeated measures ANOVA with TIME as a within-subject factor and CONDITION as a between-subject factor was used to analyze treatment effects for reaching accuracy. A Fisher's PLSD (P < .05) test was then used to determine significant mean differences.
RESULTS
Experiment 1: A Prototypical PDE4 Inhibitor Rolipram Facilitates TrainingDependent Recovery of Motor Function
Motor Recovery. To evaluate PDE4 inhibitors on motor recovery, we first tested a prototypical PDE4 inhibitor, rolipram, on recovery of reaching accuracy and motor map area. Animals were trained for approximately 14 (±3) days to reach a prestroke reaching accuracy of at least 40%. A one-way ANOVA showed no prestroke differences in reaching accuracy [F(2,27) = 0.75; P > .05)]. The mean prestroke reaching accuracy was 51% for rolipram animals, 48% for vehicle animals, and 54% for nontrained animals. A repeated-measures (ANOVA) with TIME as a within-subjects factor and CONDI-TION as a between-subject factor revealed a significant main effect of TIME [F(10,180) = 2.01; P < .05)] on number of reaching attempts ( Fig. 2A) . Subsequent multiple comparisons (Fisher's PLSD; P < .05) showed both rolipram-injected and vehicle-injected animals attempted significantly fewer reaches immediately poststroke. The number of reaching attempts also significantly increased with training ( Fig. 2A) . Nontrained animals made significantly fewer reaching attempts than both the rolipram-injected and vehicle-injected animals after 10 days of training ( Fig. 2A) .
A repeated-measures ANOVA with TIME as a within-subject factor and CONDITION as a betweensubject factor revealed a significant TIME × CONDI-TION interaction [F(10,180) = 2.01; P < .05)] on reaching accuracy (Fig. 2B) . Subsequent multiple comparisons (Fishers PLSD; P < .05) showed that both rolipram-injected and vehicle-injected animals had significantly lower reaching accuracies on day 1 of rehabilitation in comparison with prestroke levels. Further comparisons (Fisher's PLSD; P < .05) showed that although animals in both conditions showed a significant increase in reaching accuracy during the 10 days of training, rolipram-injected animals had significantly higher reaching accuracies than vehicle animals by day 4 of training and maintained this difference for the remainder of the rehabilitation training (Fig. 2B) . Vehicle animals showed a progressive increase in reaching accuracy during the first 4 days of training that was followed by a significant decrease in accuracy on days 5 and 7 (Fisher's PLSD; P < .05). No significant improvements were seen in the rolipram-injected animals after 4 days of training (Fig. 2B) . Finally, rolipram-injected animals also reached a significantly greater level of final motor recovery than vehicle animals (Fig. 2C) . Nontrained animals had a significantly lower final motor recovery than both rolipram-injected and vehicleinjected animals (Fig. 2C) . This demonstrates that rolipram increased both the rate and level of motor improvement during the initial training period but that this effect plateaued within the first week of rehabilitation. At no time during training did the rolipram-injected animals show any signs of adverse drug effects such as emesis, weight loss, or lethargy. . Animals in all conditions showed a significant reduction in number of attempts on day 1 of rehabilitation. The number of attempts progressively increased with training. No significant differences in number of attempts was observed between any two conditions on any of the 10 days of training. (B) Mean (±SD) reaching accuracy both prestroke and across the 10 days of rehabilitation. Rolipram-injected animals (ROL) had significantly higher reaching accuracies than vehicleinjected (VEH) and nontrained (NT) animals as training progressed. VEH animals showed a transient decrease in reaching accuracy that occurred on days 5 and 7. (C) Mean (±SD) level of motor recovery after rehabilitation (see text). ROL animals had a greater final level of recovery than both the vehicle (VEH) and nontrained (NT) controls. VEH animals had significantly greater recovery than NT animals (*Fisher's PLSD; P < .05).
Subsequent multiple comparisons (Fisher's PLSD; P < .05) showed that the residual CFA of rolipram-injected animals was significantly greater than both vehicle-injected and nontrained animals after rehabilitation (Fig. 3A) . Vehicle-injected trained animals also had a significantly larger residual CFA than nontrained animals (Fig. 3A) . Furthermore, a one-way ANOVA with CONDITION as a between-subject factor revealed a main effect of CON-DITION on the percentage change in the area of residual CFA poststroke [F(2,27) = 5.55; P < .01)]. Subsequent multiple comparisons (Fisher's PLSD; P < .05) showed that the rolipram-injected animals had a significant increase in residual map area compared with vehicle and nontrained animals (Fig. 3B) . Vehicle animals showed a significantly smaller loss of map area compared to nontrained animals (Fig. 3B) . Thus, motor rehabilitation alone was sufficient to reduce the loss of residual map area induced by stroke whereas rolipram in combination with motor rehabilitation caused an expansion of residual map area.
A one-way ANOVA with TIME as a within-subject factor and CONDITION as a between-subject factor revealed a significant TIME × CONDITION interaction [F(2,27) = 7.29; P < .001)] on the percentage of CFA occupied by distal forelimb representations. Subsequent multiple comparisons (Fisher's PLSD; P < .05) showed that the vehicle-injected animals had a significantly greater percentage of CFA occupied by distal movement representations after rehabilitation than all 3 conditions before rehabilitation and nontrained animals after rehabilitation. Rolipram animals had a significantly greater percentage of CFA occupied by distal movements postrehabilitation than all other conditions at all other times (Fig. 3C ). The results demonstrate that motor rehabilitation alone induced a restoration and reorganization of movement representations within residual cortex. Furthermore, rolipram enhanced trainingdependent map restoration and reorganization.
Experiment 2: A Novel PDE4 Inhibitor, HT-0712, Facilitates Training-Dependent Motor Recovery in a Dose-Dependent Manner
Motor Recovery. Having established that rolipram facilitates training-dependent motor recovery and motor map plasticity, we tested a novel PDE4 inhibitor, HT-0712, that enhances CREB-dependent gene expression and ameliorates memory defects in mice carrying truncated form of CREB binding protein-a mouse model of mental retardation called Rubinsten-Taybi syndrome. 31 Animals were trained for approximately 14 (±3) days to reach a prestroke reaching accuracy of at least 40%. A one-way ANOVA showed no prestroke differences in reaching accuracy [F(4,58) = 0.84; P > .05)]. The mean prestroke reaching accuracy was 49% for vehicle-injected animals, 45% for 0.10 mg/kg HT0712-injected animals, 46% for 0.10 mg/kg HT0712-injected animals, 49% for 0.30 mg/kg HT0712-injected animals, and 50% for 0.10 mg/kg × 2 HT-0712-injected animals (Fig. 4A) . A one-way ANOVA showed no significant differences in prestroke reaching accuracy [F(4,58) = 0.82; P > .05)]. A repeated-measures ANOVA with TIME as a within-subject factor and CON-DITION as a between-subject factor revealed a significant main effect of TIME on number of reaching attempts [F(10,52) = 5.12; P < .001)]. Subsequent multiple comparisons (Fisher's PLSD; P < .05) showed that all conditions showed a significant decrease in number of reaching attempts on day 1 of rehabilitation (Fig. 4A) . The number of attempts progressively increased in all conditions as training progressed.
A repeated-measures ANOVA with TIME as a withinsubject factor and CONDITION as a between-subject factor revealed a significant TIME × CONDITION interaction [F(10,52) = 4.72; P < .001)] on reaching accuracy (Fig. 4B) . Subsequent multiple comparisons (Fisher's PLSD; P < .05) showed that the mean reaching accuracy was significantly reduced in all conditions on day 1 of rehabilitation. The mean reaching accuracy also significantly increased in all conditions with rehabilitative training. However, the 0.15 mg/kg HT0712-injected animals had a significantly higher mean reaching accuracy than all other groups after 5 days of rehabilitation (Fig. 4B) . The 0.10 mg/kg × 2 HT-0712-injected and 0.10 mg/kg HT-0712-injected animals had a significantly higher mean reaching accuracy than vehicle-injected animals after 10 days of rehabilitation. The 0.30 mg/kg HT-0712-injected and vehicle animals did not significantly differ. Furthermore, the vehicle animals exhibited a transient relapse where reaching accuracies were significantly lower on day 6 than on day 4 (Fishers PLSD; P < .05). A one-way ANOVA with CONDITION as a between-subject factor showed a main effect of CON-DITION on percentage of prestroke reaching accuracy [F(4,58) = 2.72; P < .05)]. Subsequent multiple comparisons showed the 0.15 mg/kg HT-0712-injected animals to have a significantly greater improvement than all other conditions (Fig. 4C) . The 0.10 mg/kg × 2 HT-0712-injected animals had a significantly greater improvement than the 0.30 mg/kg HT-0712-injected and vehicle-injected animals. The 0.10 mg/kg injected animals did not differ from the 0.30 mg/kg or vehicleinjected animals (Fig. 4C) . At no time during training did the HT-0712-injected animals show any signs of adverse drug effects such as emesis, weight loss, or lethargy at any of the dosages used. (Fig. 5A) .
A one-way ANOVA with CONDITION as a between-subject factor revealed a significant effect of CONDITION [F(4,58) = 4.55; P < .05)] on the percentage change in residual CFA size. The 0.15 mg/kginjected and 0.10 mg/kg × 2-injected animals had significantly greater increases in CFA size than all other conditions (Fig. 5B) . The 0.10 mg/kg-injected and 0.30 mg/kg-injected animals had significantly larger increases than the vehicle-injected animals.
A repeated-measures ANOVA with TIME as a withinsubject factor and CONDITION as a between-subject factor revealed a significant main effect of TIME [F(9,28) = 7.21; P < .01)] and CONDITION [F(4,58) = 4.95; P < .05)] on the percentage of the residual CFA occupied by distal movement representations. Subsequent multiple comparisons (Fisher's PLSD; P < 0.05) showed that all animals exhibited a significant increase in the percentage of CFA occupied by distal movement representations after rehabilitation (Fig. 5C) . Furthermore, 0.15 mg/kg HT-0712-injected animals had a significantly greater proportion of the CFA occupied by distal movement representations posttreatment than both vehicle-injected and 0.30 mg/kg HT-0712-injected animals (Fig. 5C ).
DISCUSSION
Although the neural mechanisms underlying experience-dependent recovery of function after brain injury are not fully understood, recovery is accompanied by physiological reorganization within residual neural tissue. The present experiment demonstrates the importance of experience in driving this process and shows that adjuvant pharmacological treatments can augment both recovery and functional reorganization. All animals, regardless of drug treatment, that received rehabilitative training exhibited significant improvements in motor recovery in comparison to nontrained controls. Motor rehabilitation also induced a restoration and expansion of distal representations within residual cortical areas. Furthermore, PDE4 inhibitors that modulate CREB function by enhancing cAMP signaling significantly enhanced functional recovery and cortical reorganization and after focal cortical ischemia.
Administration of either rolipram or HT-0712 significantly enhanced motor recovery, and restoration/reorganization of residual motor maps in response to motor rehabilitation. Animals in both conditions had significantly larger residual motor maps than vehicle-injected animals. Furthermore, PDE4-injected animals exhibited a greater proportion of residual maps occupied by distal representations than vehicle-injected animals. In addition, the HT-0712-treated animals that showed the greatest motor improvement also showed significantly more restoration and reorganization within residual CFA. However, the behavioral effect was dose dependent. That is, the animals receiving 0.15 mg/kg HT-0712 showed significantly enhanced motor recovery in comparison to those that were treated at doses of 0.10 mg/kg, 0.10 mg/kg × 2, and 0.30 mg/kg. The 0.10 mg/kg × 2 animals showed more recovery than the 0.10 mg/kg and 0.30 mg/kg animals. This suggests that there may be an optimal dose of this novel PDE4 inhibitor for promoting functional recovery after ischemic insult in rats. It is unclear why 0.15 mg/kg was more effective at enhancing recovery than either 0.10 mg/kg × 2 or 0.30 mg/kg. However, similar results have been found on cognitive tests where higher doses of PDE4 inhibitors were less effective than lower doses on memory enhancement. 20 Although vehicle-injected animals showed a progressive increase in reaching accuracy with training, they also exhibited a behavioral relapse approximately 5 days after onset of rehabilitation. This is consistent with previous findings reported for both rodents 8 and primates 4 after similar manipulations. Importantly, we found that the animals receiving either rolipram or HT-0712 do not relapse. Furthermore, these animals also showed larger residual motor maps and an expansion of distal forelimb movements than vehicle-injected animals. It is hypothesized that by preventing the relapse with phosphodiesterase inhibitors, the rolipram and HT-0712 animals were not forced to re-recover after the first week of training unlike the controls. That is, both control and experimental groups showed improvements over the first few days of training. Because control animals exhibited a relapse, they began the second week of training performing at lower levels than rolipram-treated and HT-0712-treated animals. This may partially explain the lower final motor recovery seen in the vehicle-injected animals as compared with the rolipram and HT-0712 animals.
Interestingly, these results also demonstrate some disassociation between map restoration/reorganization and behavioral motor recovery. All animals receiving HT-0712 showed a significantly greater percentage increase in residual map area than vehicle-injected animals. Indeed these groups showed expansion beyond the size of the prestroke residual CFA. Thus, animals receiving 0.15 mg/kg or 0.10 mg/kg × 2 HT-0712 all showed significantly greater residual CFAs than all other groups. However, only animals treated with a single dose (0.15 mg/kg) or twice a day with 0.10 mg/kg showed significantly greater motor recovery after rehabilitation. Animals treated with a single low dose (0.10 mg/kg) or high dose (0.30 mg/kg) of HT-0712 were not significantly different from controls. It is noteworthy that we previously observed similar results using cortical stimulation where some forms of stimulation induced map expansion without significantly improving performance. 8 Thus there may not be a linear relationship between neurophysiological plasticity, as measured using ICMS, and final motor recovery. The results also suggest that there may be a critical amount of expansion of motor map area beyond the original boundaries that is required before motor performance is significantly altered above that observed with standard rehabilitation. It is also important to point out that none of the HT-0712-injected animals exhibited the behavioral relapse seen in vehicle-injected animals. It is possible that although the increased motor map area was related to this transient behavioral difference and further rehabilitation in these animals might produce additional behavioral gains.
Although the specific cellular changes underlying behavioral and neurophysiological recovery are unknown, there is considerable evidence that motor map integrity and plasticity is dependent on synaptic connectivity. First, skill learning-induced map reorganization is accompanied by synaptogenesis within intact motor cortex. 11, 12 Second, local inhibition of protein synthesis causes a loss of synapses within motor cortex that is accompanied by a reduction in motor map area and motor impairments. 8 Finally, motor map area has been shown to increase in response to manipulations that enhance synaptic strength. 13, 45 It is hypothesized that motor map restoration/reorganization that occurs during motor rehabilitation is supported by a restoration/reorganization synaptic connectivity within the motor cortex.
1 Consistent with this, there is a significant reduction in synapse number within residual motor cortex after focal ischemic infarction. 46 Both the loss of synapses and motor map area could be restored with motor rehabilitation. We hypothesize that phosphodiesterase inhibitors may act by promoting synapse formation within residual cortex, which in turn, supports motor map restoration and reorganization. Indeed, PDE4 inhibitors have been shown to increase synaptophysin reactivity within residual neural tissue after ischemia. 30 The present findings further demonstrate that understanding experience-dependent brain plasticity in both intact and damaged systems can aid in the development of novel therapeutic interventions. PDE4 inhibitors may be used to develop more effective stroke rehabilitative treatments.
